Today's Reuters Health News Headlines - Yahoo! News:
|
|
University of Colorado clamps down on "pot fest" but many light up
Fri,20 Apr 2012 07:36 PM PDT
Reuters -  BOULDER, Colo. (Reuters) - The University of Colorado sought on Friday to clamp down on a huge annual marijuana fest, but after initially restricting access to the school, police later stood back and watched hundreds of people light up in a campus field. Three protesters who crossed police lines at the Boulder campus were arrested for trespassing and about 11 others cited, but a confrontation thought possible between protesters and police never materialized. ...
Full Story | Top |
FDA says nanotech may need extra safety tests
Fri,20 Apr 2012 02:20 PM PDT
Reuters - WASHINGTON (Reuters) - U.S. health regulators said consumer products that use nanotechnology may have unknown effects on the human body, and advised food and cosmetic companies to further study the safety of these tiny particles. The U.S. Food and Drug Administration issued two draft guidelines on Friday calling for more studies, putting, for now, much of the onus for safety on companies. The FDA also rejected a consumer group's petition from 2006 that urged a separate category of regulation for nanotechnology due to its "unique human health and environmental risks. ... Full Story | Top |
Catholic nuns group "stunned" by Vatican slap
Fri,20 Apr 2012 02:07 PM PDT
Reuters -  CHICAGO (Reuters) - A prominent U.S. Catholic nuns' group said on Thursday it was "stunned" that the Vatican reprimanded it for spending too much time on poverty and social justice concerns and not enough on abortion and gay marriage. In a stinging report on Wednesday, the Vatican said the Leadership Conference of Women Religious had been "silent on the right to life" and had failed to make the "Biblical view of family life and human sexuality" a central plank in its agenda. ...
Full Story | Top |
Big regional differences in glaucoma diagnosis found
Fri,20 Apr 2012 01:46 PM PDT
Reuters - NEW YORK (Reuters Health) - A new analysis of Medicare records finds dramatic differences across the U.S. in rates of new glaucoma diagnoses, suggesting the eye disease is likely being overdiagnosed in some regions and underdiagnosed in others, researchers said. ... Full Story | Top |
Mexico's conservatives bet on woman presidential hopeful
Fri,20 Apr 2012 01:16 PM PDT
Reuters -  MEXICO CITY (Reuters) - Mexico's ruling conservatives took a bold step by becoming the first major party to nominate a woman presidential candidate, but Josefina Vazquez Mota is struggling to close a big gap with the front-runner, hamstrung by internal party divisions. Three weeks into a compressed campaign season before the July 1 vote, Vazquez Mota trails Enrique Pena Nieto from the opposition Institutional Revolutionary Party, or PRI, by double digits in most opinion polls. ...
Full Story | Top |
Colorado lights up pot debate by blazing regulatory trail
Fri,20 Apr 2012 12:54 PM PDT
Reuters - DENVER (Reuters) - At a Denver dispensary for medical marijuana, state inspector Mark Brown makes his usual checks, verifying that employees wear name-tag licenses and the video surveillance system works. The store is a laid-back place with a popcorn machine, a "Reefer Madness" movie poster and plenty of pot, sold both mixed into candy and as buds. Brown mingles with the staff, among them a tattooed man rolling joints in a side room. Fellow inspector Paul Schmidt, formerly an undercover agent with the Drug Enforcement Administration, checks on the facility's marijuana-growing operation. ...
Full Story | Top |
Fatigue after early breast cancer often fades: study
Fri,20 Apr 2012 12:20 PM PDT
Reuters -  NEW YORK (Reuters Health) - Many people treated for cancer are worn out for a time, but new findings suggest that long-lasting fatigue may be less common than thought -- at least for women with early-stage breast cancer. The study, of 218 women treated for early breast cancer, found that almost one-third had "cancer-related fatigue" at the end of treatment. But far fewer -- six percent -- still had the problem a year later. That suggests for most women with the disease post-treatment fatigue will fade with some time, the researchers report in the Journal of Clinical Oncology. ...
Full Story | Top |
Vatican crackdown on U.S. nuns a long time brewing
Fri,20 Apr 2012 11:45 AM PDT
Reuters - (Reuters) - When Pope John Paul II arrived in the United States in 1979, the president of the nation's most powerful organization of nuns met him with a challenge. In a bold welcoming address, Sister Theresa Kane called on the pope to include women "in all ministries of our church," including the priesthood. The pope sat silent, his expression stony. That moment did not change Vatican policy. But it unveiled growing tensions between the Vatican and American nuns. ... Full Story | Top |
Statins don't reduce melanoma risk: study
Fri,20 Apr 2012 11:36 AM PDT
Reuters - NEW YORK (Reuters Health) - Despite earlier indications that people taking statins might have a reduced risk of developing melanoma, a large new study of women finds the popular cholesterol-lowering drugs do nothing to prevent the deadly skin cancer. "For primary prevention (of melanoma) I think we're putting the nail into the coffin of that theory," said Dr. Robert Dellavalle, chief of dermatology at the Denver VA Medical Center, who was not involved in the new research. Melanoma is the most lethal of the skin cancers, with 70,000 new cases diagnosed in the U.S. ... Full Story | Top |
Fish oil supplements don't help MS patients: study
Fri,20 Apr 2012 11:14 AM PDT
Reuters - NEW YORK (Reuters Health) - Many people with multiple sclerosis take fish oil pills with the hope of keeping neurological symptoms from getting worse, but a new study suggests the extra omega-3 fatty acids may not be doing them any good. Because there is no effective cure for the autoimmune disease, many patients have turned to supplements that are known to affect the immune system and inflammation -- and therefore could theoretically slow the progression of disease in the brain. But so far, evidence that a supplement-boosted diet can help people with MS has been lacking. ... Full Story | Top |
S.Africa's Aspen buys $263 mln of drugs from GSK
Fri,20 Apr 2012 10:15 AM PDT
Reuters - LONDON/JOHANNESBURG (Reuters) - Aspen Pharmacare will pay $263 million for GlaxoSmithKine Plc's international over-the-counter brands, the two companies said on Friday, giving the South African drug maker a stronger presence in popular painkillers. The sale is the latest move by GSK to fine-tune its consumer healthcare business and follows the divestment of other over-the-counter (OTC) brands in North America and Europe. Net cash proceeds from the transaction are expected to be approximately 135 million pounds and will be returned to GSK shareholders during 2012. Shares in Aspen closed 5. ... Full Story | Top |
GE profit, revenue top Wall Street forecasts
Fri,20 Apr 2012 10:06 AM PDT
Reuters -  (Reuters) - General Electric Co topped Wall Street's profit and revenue forecasts for the first quarter, helped by strong demand for energy equipment and railroad locomotives. The largest U.S. conglomerate said on Friday industrial orders had risen 20 percent in the quarter and that selling prices had improved in most of its businesses. This should help Chief Executive Officer Jeff Immelt achieve his goal of boosting profit margins this year. "Global markets are improving, but volatility remains," Immelt told investors on a conference call. ...
Full Story | Top |
SkyePharma asthma drug wins European backing
Fri,20 Apr 2012 09:39 AM PDT
Reuters - LONDON (Reuters) - SkyePharma said on Friday its lead product, asthma therapy Flutiform, had been recommended for approval by European regulators, doubling the value of the group's shares. Flutiform was referred to the European Medicines Agency (EMA) last year after member states could not reach unanimous agreement on the drug, which will compete with GlaxoSmithKline's Advair and AstraZeneca's Symbicort in the multi-billion dollar respiratory drugs market A positive opinion from the EMA is usually rubber stamped by the European Commission in a matter of months. ... Full Story | Top |
EU agency endorses Bristol, Astra diabetes drug
Fri,20 Apr 2012 09:23 AM PDT
Reuters - LONDON (Reuters) - European regulators recommended approval of a new type 2 diabetes drug from AstraZeneca and Bristol-Myers Squibb on Friday, in a decision that contrasts starkly with its failure to win approval in the United States. Dapagliflozin, which will be sold under the brand name Forxiga, is a new type of diabetes drug designed to allow more sugar to be excreted with urine and has the potential to be the first to treat the disease independent of the hormone insulin. ... Full Story | Top |
Birth defects more common in IVF babies: study
Fri,20 Apr 2012 08:40 AM PDT
Reuters -  (Reuters) - Babies conceived through certain fertility treatment techniques are about one-third more likely to have a birth defect than babies conceived without any extra help from technology, according to a review of several dozen studies. However, the researchers - whose findings were published in the journal Fertility and Sterility - did not determine why fertility treatments are tied to a higher risk of birth defects or whether the technology is even responsible. ...
Full Story | Top |
| |
|
No comments:
Post a Comment